TESTING 89
Figure 17: Improvement of KP between T0 (left) and after 4 weeks application of Salinicoccus lysate (right).
showed a positive impact on KP parameters (Table 3). The density of KP was significantly decreased by 10.5% versus a slight increase of the placebo treated KP site (p<0.01). In the same way, KP total perimeter was reduced by 7.5% and this was significant compared to placebo site (p<0.05). The illustration provided by Mountains (Fig 17) shows the KP decrease.
Conclusion Using different tools, we developed several methods to quantify and illustrate keratosis pilaris. The dermatoscopic camera allowed us to illustrate the KP with 2D or 3D pictures. The 2D pictures provided a clear view of the lesions with true colours, while 3D views allowed us to see the volume of lesions. Moreover, thanks to camera calibration, it is possible to quantify redness, dryness and additional 3D parameters such as Sa, Sq, Sz. This quantification remains unfortunately
manual with the necessary selection of each KP lesions, further studies being necessary to improve this issue. The quantification method with
replicas and fringes projection allowed us to calculate interesting parameters such as density, volume, perimeter and surface. After a setup phase, both software AEVA and Mountains can be used for KP quantification and we have assessed this in a clinical study. It was interesting to associate automatic quantification part from AEVA and illustrative 3D representation from Mountains. In conclusion, both fringe projection
and dermatoscopic camera are of interest for sharp evaluation of ingredients acting on keratosis pilaris.
PC References
1 Hwang S, Schwatrz RA. Keratosis pilaris: a common follicular hyperkeratosis. Cutis 2008; 82: 177-180.
2 Kootiratrakarn T, Kampirapap K, Chunasewee
Table 3: Variation of keratosis pilaris after 4 weeks cream application Quantity of KP (20x20mm surface)
Salinicoccus Lysate T0
Mean Sd
Variation vs. T0 (%) Significance vs. Placebo April 2020 p< 0.01
23.7 7.6
Placebo
T4w 21.2 73
-10.5% T0
20.9 7.2
T4w 21.5 9.2
-2.9% p< 0.05 PERSONAL CARE EUROPE
C. Epidermal barrier in the treatment of keratosis pilaris. Dermatol. Res. Practice 2015; ID205012, 5p.
3 Poskitt L, Wilkinson JD. Natural history of keratosis pilaris. Br. J. Dermatol., 1994; 130: 711-713.
4 Plascencia Gomez A, Vega Memije ME, Torrez Tamayo M, Rodriguez Carreon AA. Skin disorders in overweight and obese patients and their relationship with insulin. Actas Dermosifiliogr. 2014; 105: 178-185.
5 Yosipovitch G, Mevorah B, Mashiach J, Chan YH, David M. High body mass index, dry scale leg skin and atopic conditions are highly associated with keratosis pilaris. Dermatology, 2000 ; 201 : 34-36.
6 Gruber R, Sugarman JL, Crumrine D, Hupe M, et al. Sebaceous gland, hair shaft and epidermal barrier abnormalities in keratosis pilaris with and without filaggrin deficiency. Am. J. Pathol. 2015; 185, 1012-1021.
7 Leong WMS, Aw CWD. Nilotinid-induced keratosis pilaris. Case Rep. Dermatol., 2016; 8: 91-96.
Salinicoccus Lysate T0
106.2 29.1
Total perimeter of KP (mm; 20x20mm surface) Placebo
T4w 98.2 35.7
-7.5% T0
98.9 24.9
T4w 103 45.5
+4.1%
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196
